FDA Revokes Roche Avastin Approval in Breast Cancer

(TheStreet) -- Roche's(

) top-selling cancer drug Avastin has lost its approval as a breast cancer therapy, ruled U.S. Food and Drug Administration Commissioner Margaret Hamburg Friday. Hamburg's decision to revoke Avastin's approval is the denouement of a controversial, year-long fight that saw doctors, the FDA, Roche and breast cancer advocates all arguing over whether the Avastin's benefits outweighed its safety risks. In the end, Hamburg affirmed the move made by FDA in December 2010 calling for Avastin to lose its breast cancer clearance while remaining on the market for lung, colon, brain and kidney cancers.

.